After weight loss, heart disease, and liver disease, can semaglutide also "fight dementia"? Novo Nordisk "places great hope" on it.
```
Since the launch of semaglutide seven years ago, the application of Novo Nordisk's GLP-1 drug has expanded from obesity and diabetes to heart and liver diseases. At present, Novo Nordisk is testing its efficacy for Alzheimer's disease.
This fall, Novo Nordisk will announce the clinical trial